Edwards Lifesciences Corp (EW)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$84.01
Buy
$87.50
$-1.56 (-1.78%)
Prices updated at 11 Jun 2026, 00:41 EDT
| Prices minimum 15 mins delay
Prices in USD
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, in ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Nicholas J. Valeriani
CEO
Mr. Bernard J. Zovighian
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
16,000
Head office
One Edwards Way
Irvine
United States
92614
Key personnel
Owner name | Salary |
|---|---|
Ms. Theodora Mistras Corporate Vice President and Chief Financial Officer | - |
Mr. Donald E. Bobo,Jr Corporate Vice President, Strategy and Corporate Development | 0.76m |
Mr. Kieran T. Gallahue Independent Director | 0.09m |
Mr. Nicholas J. Valeriani Chairman of the Board | 0.09m |
Mr. Paul A. Laviolette Independent Director | 0.11m |
Mr. Steven R. Loranger Independent Director | 0.09m |
Ms. Leslie Stone Heisz Independent Director | 0.12m |
Dr. David T. Feinberg, M.D.,PhD Independent Director | 0.09m |
Mr. Bernard J. Zovighian Director and Chief Executive Officer | 1.19m |
Mr. Daveen Chopra Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies | 0.67m |
Ms. Ramona A. Sequeira Independent Director | 0.09m |
Mr. Wayne T. Markowitz General Manager and Senior Vice President, Surgical Structural Heart | - |
Ms. Annette Bruls Corporate Vice President, EMEACLA | 0.73m |
Mr. Daniel J. Lippis Corporate Vice President, Transcatheter Aortic Valve Replacemen | - |
Ms. Leslie C. Davis Independent Director | 0.09m |
Mr. Andrew M. Dahl Principal Accounting Officer, Senior Vice President and Corporate Controller | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard Group Inc | 70,079,435 |
| BlackRock Inc | 52,590,933 |
| Vanguard Capital Management, LLC | 37,727,792 |
| Vanguard Portfolio Management, LLC | 26,407,018 |
| State Street Corp | 26,296,399 |
Director dealings
Date | Action |
|---|---|
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 11 Dec 2025 | - |
| 10 Dec 2025 | - |
| 10 Dec 2025 | - |
| 10 Dec 2025 | - |
| 09 Dec 2025 | - |
| 09 Dec 2025 | - |
| 09 Dec 2025 | - |
| 09 Dec 2025 | - |
| 08 Dec 2025 | - |
| 10 Dec 2025 | - |
| 09 Dec 2025 | - |
| 08 Dec 2025 | - |
| 08 Dec 2025 | - |
Please note that past performance is not a reliable indicator of future returns.